Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|December 3, 2020

Lonza Announces Long-Term Collaboration with Global Biopharma Company

Lonza has formed a long-term, strategic collaboration with a global biopharma company for bioconjugation.

Lonza has announced, in a Dec. 2, 2020 press release, that it has formed a long-term, strategic collaboration with a global biopharma company for bioconjugation. The collaboration is expected to generate 200 new jobs in the Visp (Switzerland) biopark and operations will start at the end of 2022.

As per the terms of the agreement, Lonza will build two new customer-dedicated conjugation suites for the commercialization of antibody-drug conjugates (ADCs). The suites will total 1500 m2 of active manufacturing space and will form part of Lonza’s Ibex Dedicate model—a technology-agnostic supply solution.

“Bioconjugates represent an exciting class of molecules that are proving their worth and making a real difference to patients suffering from diseases such as cancer,” said Pierre-Alain Ruffieux, CEO, Lonza, in the press release. “From a manufacturing point of view, antibody-drug conjugates are challenging to produce, and we will be ensuring that our partner can de-risk supply and scale-up rapidly at this crucial moment of commercialization.”

“This collaboration demonstrates the power behind our Ibex Dedicate model, providing rapid and reliable delivery of complex therapeutics and tailored to individual customer needs,” added Jean-Christophe Hyvert, chief commercial officer, Lonza, in the press release. “Our Visp (CH) site now has all the elements required for antibody-drug conjugates at one site and this provides significant supply chain simplification and other logistical benefits to our customers, enabling them to reach patients faster.”

Source: Lonza


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.